Nasdaq · CIK 0001709941
BIOA BioAge Labs, Inc.
B
75 / 100
Material weaknesses
2
Restatements
0
Auditor changes
0
Late filings
0
Quarters with open weakness
1
Remediations
1
Deductions
40
Remediation credit
15
Trailing 24 months from 2024-11-07. Rubric v1. How this is scored.
Disclosures, in the company's words
“Management had also determined that it did not maintain effective information technology controls in the areas of user access, change management and segregation of duties, within the systems supporting our accounting and reporting processes.”
“In preparing the financial statements as of and for the years ended December 31, 2023 and 2022, management previously determined it had not maintained appropriately designed entity-level controls impacting the control environment, risk assessment procedures and monitoring activities to prevent or detect material misstatements to our condensed consolidated financial statements, which constituted material weaknesses.”
Remediation disclosed
- 10-Q · filed 2026-11-05 · source filing ↗
“During the fiscal year ended December 31, 2024, we successfully completed the testing necessary to conclude that the material weaknesses have been remediated.”
- 10-Q · filed 2026-11-05 · source filing ↗
“We previously identified material weaknesses in our internal control over financial reporting. Although we have remediated these material weaknesses, we may identify additional material weaknesses or other deficiencies in the future”
Filings read
- 10-Q · 2026-11-05read
- 10-Q · 2026-08-05queued
- 10-Q · 2026-05-08queued
- 10-K · 2026-03-24queued
- 10-Q · 2025-11-06queued
- 10-Q · 2025-05-06queued
- 10-K · 2025-03-20queued
- 10-Q · 2024-11-07queued
Think something here is wrong? Request a correction. Open corrections hide the affected disclosure until resolved.